Newer treatment options for patients with moderate-to-severe psoriatic disease.
Roebuck
Heather L
HL
M. Siegel MD, P.C. Diseases-Surgery of the Skin, Waterford, MI, USA.
D000068879:Adalimumab; D000077944:Alefacept; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001294:Attitude to Health; D001623:Betamethasone / Q000627:therapeutic use; D001828:Body Image; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D002990:Clobetasol / Q000031:analogs & derivatives / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D016903:Drug Monitoring; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; C055085:calcipotriene; D001623:Betamethasone; D002990:Clobetasol; D000069285:Infliximab; D000077944:Alefacept; D002117:Calcitriol; D000068879:Adalimumab; D000068800:Etanercept; C472181:efalizumab